 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH, a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022. An interim analysis from COSMOS-CRC-01, a large, prospective, observational study, shows that 